source,date,assertionType,evidenceType,exactText,modality,statementType,drug1Lab,drug1Type,drug1Role,dose1,drug2Lab,drug2Type,drug2Role,dose2,objectRegimens,objectFormulation,objectDuration,preciptRegimens,preciptFormulation,preciptDuration,numOfParticipants,auc,aucType,aucDirection,cl,clType,clDirection,cmax,cmaxType,cmaxDirection,t12,t12Type,t12Direction
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 14:35:23 -0700,DDI-clinical-trial,evidence-supports,"Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.",ncit:positive,ncit:quantitative,iloperidone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,3,ketoconazole,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,SD,Oral,1,BID,Oral,4,19,57,Percent,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 15:12:19 -0700,DDI-clinical-trial,evidence-supports,"Dextromethorphan: A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in the maximum plasma concentrations (Cmax)of dextromethorphan. Thus, an interaction between iloperidone and other CYP2D6 substrates is unlikely.",ncit:positive,ncit:quantitative,dextromethorphan,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,80,iloperidone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,3,SD,Oral,1,SD,Oral,1,UNK,17,Percent,Increase,UNK,UNK,UNK,26,Percent,Increase,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 14:46:00 -0700,DDI-clinical-trial,evidence-supports,"Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. ",ncit:positive,ncit:quantitative,fluoxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,P88,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,3,SD,Oral,1,BID,Oral,21,23,2 to 3,Fold,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 14:55:02 -0700,DDI-clinical-trial,evidence-supports,"Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. ",ncit:positive,ncit:quantitative,P88,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,8 or 12,paroxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,BID,Oral,UNK,Daily,Oral,5 to 8,UNK,UNK,UNK,UNK,UNK,UNK,UNK,1.6,Fold,Decrease,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 14:55:02 -0700,DDI-clinical-trial,evidence-supports,"Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. ",ncit:positive,ncit:quantitative,paroxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,P95,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,8 or 12,BID,Oral,UNK,Daily,Oral,5 to 8,UNK,UNK,UNK,UNK,UNK,UNK,UNK,50,Percent,Decrease,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 14:46:00 -0700,DDI-clinical-trial,evidence-supports,"Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. ",ncit:positive,ncit:quantitative,fluoxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,iloperidone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,3,SD,Oral,1,BID,Oral,21,23,2 to 3,Fold,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 15:19:40 -0700,DDI-clinical-trial,evidence-challenges,luoxetine: A single 3 mg dose of iloperidone had no effect on the pharmacokinetics of fluoxetine (20 mg twice daily). ,ncit:negative,ncit:quantitative,fluoxetine,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,20,iloperidone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,3,BID,Oral,UNK,SD,Oral,1,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 14:49:58 -0700,DDI-clinical-trial,evidence-supports,"Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. ",ncit:positive,ncit:quantitative,iloperidone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,8 or 12,paroxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,BID,Oral,UNK,Daily,Oral,5 to 8,UNK,UNK,UNK,UNK,UNK,UNK,UNK,1.6,Fold,Increase,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 14:35:23 -0700,DDI-clinical-trial,evidence-supports,"Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.",ncit:positive,ncit:quantitative,ketoconazole,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,P88,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,3,SD,Oral,1,BID,Oral,4,19,55,Percent,Increase,UNKUNUNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 15:23:59 -0700,DDI-clinical-trial,evidence-supports,"Midazolam (a sensitive CYP 3A4 substrate): A study in patients with schizophrenia showed a less than 50% increase in midazolam total exposure at iloperidone steady state (14 days of oral dosing at up to 10 mg iloperidone twice daily) and no effect on midazolam Cmax. Thus, an interaction between iloperidone and other CYP3A4 substrates is unlikely.",ncit:positive,ncit:quantitative,iloperidone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,up to 10,midazolam,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,UNK,Oral,UNK,BID,Oral,14,UNK,less than 50,Percent,Increase,UNK,UNK,UNK,no effect,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 14:46:00 -0700,DDI-clinical-trial,evidence-supports,"Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. ",ncit:positive,ncit:quantitative,fluoxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,P95,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,3,SD,Oral,1,BID,Oral,21,23,50,Percent,Decrease,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html ,2015-11-29 14:38:11 -0700,DDI-clinical-trial,evidence-supports,"Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.",ncit:positive,ncit:quantitative,ketoconazole,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,P95,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,3,SD,Oral,1,BID,Oral,4,19,35,Percent,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html,2015-11-29 18:49:20 -0500,DDI-clinical-trial,evidence-challenges,Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. Dose adjustment for digoxin is not recommended.,ncit:negative,ncit:quantitative,digoxin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,Risperidone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,0.25,UNK,Oral,UNK,BID,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html,2015-11-29 16:36:20 -0700,DDI-clinical-trial,evidence-challenges,"Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. Dose adjustment for valproate is not recommended.",ncit:negative,ncit:quantitative,valproate,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,1000,risperidone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,4,Daily,Oral,UNK,QD,Oral,UNK,21,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html,2015-11-29 16:36:20 -0700,DDI-clinical-trial,evidence-challenges,Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (n=13). Dose adjustment for lithium is not recommended.,ncit:negative,ncit:quantitative,lithium,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,risperidone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,3,UNK,Oral,UNK,BID,Oral,UNK,13,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html,2015-11-29 16:36:20 -0700,DDI-clinical-trial,evidence-supports,"Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. Dose adjustment for valproate is not recommended.",ncit:positive,ncit:quantitative,risperidone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,4,valproate,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,1000,Daily,Oral,UNK,QD,Oral,UNK,21,UNK,UNK,UNK,UNK,UNK,UNK,20,Percent,Increase,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html,2015-11-29 13:52:49 -0700,DDI-clinical-trial,evidence-challenges,Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Drug Interactions (7.4)].,ncit:negative,ncit:quantitative,salicylic acid,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,150,BRINTELLIX,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,Daily,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNKUNUNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html,2015-11-29 13:36:22 -0700,DDI-clinical-trial,evidence-challenges,No clinically relevant effect was observed on steady state lithium exposure following coadministration with multiple daily doses of BRINTELLIX.,ncit:negative,ncit:quantitative,lithium,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,BRINTELLIX,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,UNK,Oral,UNK,UNK,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html,2015-11-29 13:44:17 -0700,DDI-clinical-trial,evidence-challenges,Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Drug Interactions (7.4)].,ncit:negative,ncit:quantitative,BRINTELLIX,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,aspirin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,150,Daily,Oral,UNK,UNK,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html,2015-11-29 15:59:31 -0500,DDI-clinical-trial,evidence-challenges,"Because vortioxetine is highly bound to plasma protein, coadministration of BRINTELLIX with another drug that is highly protein bound may increase free concentrations of the other drug. However, in a clinical study with coadministration of BRINTELLIX (10 mg/day) and warfarin (1 mg/day to 10 mg/day), a highly protein-bound drug, no significant change in INR was observed [see Drug Interactions (7.2)].",ncit:negative,ncit:quantitative,warfarin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,1 to 10,BRINTELLIX,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,Daily,Oral,UNK,UNK,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html,2015-11-29 13:38:00 -0700,DDI-clinical-trial,evidence-challenges,Multiple doses of BRINTELLIX did not affect the pharmacokinetics or pharmacodynamics (composite cognitive score) of diazepam.,ncit:negative,ncit:quantitative,diazepam,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,BRINTELLIX,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,UNK,Oral,UNK,UNK,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html,2015-11-29 13:52:49 -0700,DDI-clinical-trial,evidence-challenges,"Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2).",ncit:negative,ncit:quantitative,bupropion,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,BRINTELLIX,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,UNK,Oral,UNK,UNK,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html,2015-11-29 13:57:37 -0700,DDI-clinical-trial,evidence-challenges,"Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2).",ncit:negative,ncit:quantitative,BRINTELLIX,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,warfarin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,UNK,Oral,UNK,UNK,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html,2015-11-29 13:57:37 -0700,DDI-clinical-trial,evidence-challenges,"Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2)",ncit:negative,ncit:quantitative,diazepam,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,BRINTELLIX,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,UNK,Oral,UNK,UNK,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html,2015-11-29 13:42:04 -0700,DDI-clinical-trial,evidence-challenges,"Following coadministration of stable doses of warfarin (1 to 10 mg/day) with multiple daily doses of BRINTELLIX, no significant effects were observed in INR, prothrombin values or total warfarin (protein bound plus free drug) pharmacokinetics for both R- and S-warfarin [see Drug Interactions (7.4)].",ncit:negative,ncit:quantitative,BRINTELLIX,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,warfarin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,1 to 10,Daily,Oral,UNK,UNK,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:01:39 -0700,DDI-clinical-trial,evidence-supports,"When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. ",ncit:positive,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,triazolam,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,0.25,SD,Oral,1,BID,Oral,UNK,UNK,4,Fold,Increase,UNK,UNK,UNK,1.7,Fold,Increase,4,Fold,Increase
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:37:19 -0700,DDI-clinical-trial,evidence-challenges,"Phenytoin – Pretreatment for 7 days with 200 mg BID of nefazodone had no effect on the pharmacokinetics of a single 300 mg oral dose of phenytoin. However, due to the nonlinear pharmacokinetics of phenytoin, the failure to observe a significant effect on the single-dose pharmacokinetics of phenytoin does not preclude the possibility of a clinically significant interaction with nefazodone when phenytoin is dosed chronically. ",ncit:negative,ncit:quantitative,Phenytoin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,300,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,SD,Oral,1,BID,Oral,7,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:29:38 -0700,DDI-clinical-trial,evidence-challenges,"Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,Lorazepam,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,5,SD,Oral,1,BID,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:11:00 -0700,DDI-clinical-trial,evidence-supports,"When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold.",ncit:positive,ncit:quantitative,alprazolam,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,1,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,BID,Oral,UNK,BID,Oral,UNK,UNK,2,Fold,Increase,UNK,UNK,UNK,2,Fold,Increase,2,Fold,Increase
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:04:35 -0700,DDI-clinical-trial,evidence-supports,"With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%).",ncit:positive,ncit:quantitative,buspirone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,5,hydroxynefazodone,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,250,BID,Oral,UNK,BID,Oral,UNK,UNK,17,Percent,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:26:49 -0700,DDI-clinical-trial,evidence-challenges, Pharmacodynamic effects of haloperidol were generally not altered significantly. There were no changes in the pharmacokinetic parameters for nefazodone,ncit:negative,ncit:quantitative,haloperidol,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,5,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,BID,Oral,UNK,SD,Oral,1,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 13:20:54 -0700,drug-drug-interaction,evidence-supports,"There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. Both cyclosporine and tacrolimus are substrates of CYP3A4, and nefazodone is known to inhibit this enzyme. If either cyclosporine or tacrolimus is administered with nefazodone, blood concentrations of the immunosuppressive agent should be monitored and dosage adjusted accordingly.",ncit:positive,ncit:Qualitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,,cyclosporine,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 13:14:12 -0700,drug-drug-interaction,evidence-supports,"Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.",ncit:positive,ncit:Qualitative,mCPP,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,,Lithium,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 13:58:57 -0700,DDI-clinical-trial,evidence-supports,"Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone",ncit:positive,ncit:quantitative,alprazolam,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:29:38 -0700,DDI-clinical-trial,evidence-challenges," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively",ncit:negative,ncit:quantitative,fluoxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,HO-NEF,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,200,BID,Oral,UNK,QD,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 15:22:19 -0500,drug-drug-interaction,evidence-supports,"There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. Both cyclosporine and tacrolimus are substrates of CYP3A4, and nefazodone is known to inhibit this enzyme. If either cyclosporine or tacrolimus is administered with nefazodone, blood concentrations of the immunosuppressive agent should be monitored and dosage adjusted accordingly.",ncit:positive,ncit:Qualitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,,tacrolimus,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:47:05 -0700,DDI-clinical-trial,evidence-challenges,"Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.",ncit:negative,ncit:quantitative,propranolol,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,40,hydroxynefazodone,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,200,BID,Oral,5.5,BID,Oral,5.5,18,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:33:34 -0700,DDI-clinical-trial,evidence-supports," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively",ncit:positive,ncit:quantitative,fluoxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,mCPP,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,200,BID,Oral,UNK,QD,Oral,UNK,UNK,3 to 6,Percent,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 13:06:08 -0700,DDI-clinical-trial,evidence-supports,"HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent",ncit:positive,ncit:quantitative,atorvastatin lactone,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,40,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,SD,Oral,1,BID,Oral,6,UNK,3 to 4,Fold,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:42:44 -0700,DDI-clinical-trial,evidence-challenges,"There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.",ncit:negative,ncit:quantitative,desipramine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,75,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,150,BID,Oral,UNK,QD,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:44:04 -0700,DDI-clinical-trial,evidence-challenges,"There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.",ncit:negative,ncit:quantitative,desipramine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,75,triazole-dione,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,150,BID,Oral,UNK,QD,Oral,UNK,UNK,UNK,UNK,UNK,UNKUNUNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:51:32 -0700,DDI-clinical-trial,evidence-supports,"Buspirone – In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. ",ncit:positive,ncit:quantitative,buspirone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,2.5 or 5,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,250,BID,Oral,UNK,BID,Oral,UNK,UNK,up to 50,Fold,Increase,UNK,UNK,UNK,up to 20,Fold,Increase,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 13:56:43 -0700,DDI-clinical-trial,evidence-supports,"Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone.",ncit:positive,ncit:quantitative,triazolam,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 13:05:05 -0700,drug-drug-interaction,evidence-supports,"The coadministration of triazolam and nefazodone causes a significant increase in the plasma level of triazolam (see WARNINGS and PRECAUTIONS), and a 75% reduction in the initial triazolam dosage is recommended if the two drugs are to be given together. ",ncit:positive,ncit:Qualitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,,triazolam,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:51:40 -0700,DDI-clinical-trial,evidence-challenges,"Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,Lithium,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,500,BID,Oral,5,BID,Oral,5,13,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:51:10 -0700,DDI-clinical-trial,evidence-supports,"Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.",ncit:positive,ncit:quantitative,propranolol,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,40,m-chlorophenylpiperazine,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,200,BID,Oral,5.5,BID,Oral,5.5,18,28,Percent,Increase,UNK,UNK,UNK,23,Percent,Increase,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:40:46 -0700,DDI-clinical-trial,evidence-challenges,"Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. ",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,150,Desipramine,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,75,QD,Oral,UNK,BID,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:03:19 -0700,DDI-clinical-trial,evidence-challenges,Nefazodone plasma concentrations were unaffected by triazolam.,ncit:negative,ncit:quantitative,triazolam,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,0.25,Nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,BID,Oral,UNK,SD,Oral,1,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:05:41 -0700,DDI-clinical-trial,evidence-challenges,"When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered for one week, no change in the steady-state pharmacokinetics of either nefazodone or cimetidine was observed compared to each dosed alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,cimetidine,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,300,QID,Oral,7,BID,Oral,7,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:57:09 -0700,DDI-clinical-trial,evidence-supports,"Buspirone – In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine.",ncit:positive,ncit:quantitative,1-pyrimidinylpiperazine.,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,2.5 or 5,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,250,BID,Oral,UNK,BID,Oral,UNK,UNK,about 50,Percent,Decrease,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:24:30 -0700,DDI-clinical-trial,evidence-challenges," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine.",ncit:negative,ncit:quantitative,fluoxetine,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,20,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,QD,Oral,UNK,BID,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:33:28 -0700,DDI-clinical-trial,evidence-challenges,"Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,Lorazepam,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,2,BID,Oral,UNK,BID,Oral,UNK,UNK,UNKUNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:01:56 -0700,DDI-clinical-trial,evidence-supports,"With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%).",ncit:positive,ncit:quantitative,buspirone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,5,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,250,BID,Oral,UNK,BID,Oral,UNK,UNK,23,Percent,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:52:47 -0700,DDI-clinical-trial,evidence-challenges,"Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.",ncit:negative,ncit:quantitative,HO-NEF,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,200,Lithium,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,500,BID,Oral,5,BID,Oral,5,13,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:27:03 -0700,DDI-clinical-trial,evidence-challenges,"When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively.",ncit:negative,ncit:quantitative,fluoxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,BID,Oral,UNK,QD,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 13:04:34 -0700,DDI-clinical-trial,evidence-supports,"HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent",ncit:positive,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,atorvastatin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,40,SD,Oral,1,BID,Oral,6,UNK,3 to 4,Fold,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:11:14 -0700,DDI-clinical-trial,evidence-challenges,"When nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,theophylline,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,600 to 1200,BID,Oral,UNK,Daily,Oral,UNK,UNK,UNK,UNK,UNK,UNKUNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:37:36 -0700,DDI-clinical-trial,evidence-supports,"Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol.",ncit:positive,ncit:quantitative,propranolol,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,40,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,BID,Oral,5.5,BID,Oral,5.5,18,14,Percent,Decrease,UNK,UNK,UNK,30,Percent,Decrease,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 13:04:34 -0700,DDI-clinical-trial,evidence-supports,"HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent",ncit:positive,ncit:quantitative,simvastatin acid,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,200,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,40,BID,Oral,6,SD,Oral,1,UNK,20,Fold,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:07:38 -0700,DDI-clinical-trial,evidence-supports,"With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%)",ncit:positive,ncit:quantitative,mCPP,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,250,buspirone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,5,BID,Oral,UNK,BID,Oral,UNK,UNK,9,Percent,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:24:14 -0700,DDI-clinical-trial,evidence-supports,"Haloperidol – When a single oral 5 mg dose of haloperidol was coadministered with nefazodone (200 mg BID) at steady state, haloperidol apparent clearance decreased by 35% with no significant increase in peak haloperidol plasma concentrations or time of peak.",ncit:positive,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,haloperidol,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,5,SD,Oral,1,BID,Oral,UNK,UNK,UNK,UNK,UNK,35,Percent,Decrease,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:46:00 -0700,DDI-clinical-trial,evidence-supports,"There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.",ncit:positive,ncit:quantitative,desipramine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,75,mCPP,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,150,BID,Oral,UNK,QD,Oral,UNK,UNK,44,Percent,Increase,UNK,UNK,UNK,48,Percent,Increase,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:09:54 -0700,DDI-clinical-trial,evidence-challenges,"When nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,theophylline,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,600 to 1200,Daily,Oral,UNK,BID,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:23:33 -0700,DDI-clinical-trial,evidence-supports,"Digoxin – When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered for 9 days to healthy male volunteers (n = 18) who were phenotyped as CYP2D6 extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by 29%, 27%, and 15%, respectively.",ncit:positive,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,digoxin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,0.2,QD,Oral,9,BID,Oral,9,18,15,Percent,Increase,UNK,UNK,UNK,29,Percent,Increase,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:47:05 -0700,DDI-clinical-trial,evidence-challenges,"Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,propranolol,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,40,BID,Oral,5.5,BID,Oral,5.5,18,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 13:08:12 -0700,DDI-clinical-trial,evidence-challenges,"HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent",ncit:negative,ncit:quantitative,pravastatin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,UNK,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,UNK,Oral,UNK,BID,Oral,6,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:37:36 -0700,DDI-clinical-trial,evidence-challenges,"Digoxin – When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered for 9 days to healthy male volunteers (n = 18) who were phenotyped as CYP2D6 extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by 29%, 27%, and 15%, respectively. Digoxin had no effects on the pharmacokinetics of nefazodone and its active metabolites. Because of the narrow therapeutic index of digoxin, caution should be exercised when nefazodone and digoxin are coadministered; plasma level monitoring for digoxin is recommended.",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,digoxin,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,0.2,BID,Oral,9,QD,Oral,9,18,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:07:13 -0700,DDI-clinical-trial,evidence-challenges,"When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered for one week, no change in the steady-state pharmacokinetics of either nefazodone or cimetidine was observed compared to each dosed alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.",ncit:negative,ncit:quantitative,cimetidine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,300,nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,BID,Oral,7,QID,Oral,7,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 14:12:47 -0700,DDI-clinical-trial,evidence-challenges,Nefazodone plasma concentrations were unaffected by alprazolam. ,ncit:negative,ncit:quantitative,Nefazodone,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,200,alprazolam,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,1,BID,Oral,UNK,BID,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:24:30 -0700,DDI-clinical-trial,evidence-challenges," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine.",ncit:negative,ncit:quantitative,norfluoxetine,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,20,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,QD,Oral,UNK,BID,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:40:46 -0700,DDI-clinical-trial,evidence-challenges,"Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. ",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,150,2-hydroxy desipramine.,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,75,QD,Oral,UNK,BID,Oral,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:07:38 -0700,DDI-clinical-trial,evidence-supports,"With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%)",ncit:positive,ncit:quantitative,hydroxynefazodone,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,250,buspirone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,5,BID,Oral,UNK,BID,Oral,UNK,UNK,17,Percent,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 13:00:53 -0700,DDI-clinical-trial,evidence-supports,"HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent.",ncit:positive,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,simvastatin,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,40,QD,Oral,1,BID,Oral,6,UNK,20,Fold,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-27 15:35:40 -0700,DDI-clinical-trial,evidence-supports,"When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively",ncit:positive,ncit:quantitative,fluoxetine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,20,triazole-dione,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,200,BID,Oral,UNK,QD,Oral,UNK,UNK,1.3,Fold,Increase,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:41:53 -0700,DDI-clinical-trial,evidence-supports,"Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol.",ncit:positive,ncit:quantitative,4-hydroxypropranolol,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,40,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,BID,Oral,5.5,BID,Oral,5.5,18,UNK,UNK,UNK,UNK,UNK,UNK,14,Percent,Decrease,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:47:19 -0700,DDI-clinical-trial,evidence-supports,"There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.",ncit:positive,ncit:quantitative,desipramine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,75,HO-NEF,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,150,BID,Oral,UNK,QD,Oral,UNK,UNK,19,Percent,Decrease,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 13:14:12 -0700,drug-drug-interaction,evidence-supports,"Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.",ncit:positive,ncit:Qualitative,triazole-dione,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,,Lithium,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 11:50:15 -0700,DDI-clinical-trial,evidence-challenges,"Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.",ncit:negative,ncit:quantitative,nefazodone,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,Lithium,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,500,BID,Oral,5,BID,Oral,5,13,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html,2015-11-29 12:47:05 -0700,DDI-clinical-trial,evidence-challenges,"Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.",ncit:negative,ncit:quantitative,propranolol,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,40,triazole-dione,dikbD2R:metabolite,dikbD2R:object-drug-of-interaction,200,BID,Oral,5.5,BID,Oral,5.5,18,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html,2015-11-29 16:18:02 -0700,DDI-clinical-trial,evidence-supports,"Co-administration of INVEGA® 6 mg once daily with carbamazepine, a strong inducer of both CYP3A4 and P-glycoprotein (P-gp), at 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration.",ncit:positive,ncit:quantitative,carbamazepine,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,200,INVEGA,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,6,QD,Oral,UNK,BID,Oral,UNK,UNK,37,Percent,Decrease,35,Percent,Increase,37,Percent,Increase,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html,2015-11-29 16:14:39 -0700,DDI-clinical-trial,evidence-challenges,"In a drug interaction study, co-administration of INVEGA® (12 mg once daily for 5 days) with divalproex sodium extended-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics (AUC24h and Cmax,ss) of valproate in 13 patients stabilized on valproate. ",ncit:negative,ncit:quantitative,divalproex sodium,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,500 to 2000,INVEGA,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,12,QD,Oral,UNK,QD,Oral,5,13,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK,UNK
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html,2015-11-29 16:15:29 -0700,drug-drug-interaction,evidence-challenges,"In a clinical study, subjects on stable doses of valproate had comparable valproate average plasma concentrations when INVEGA® 3–15 mg/day was added to their existing valproate treatment.",ncit:negative,ncit:Qualitative,INVEGA,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,,valproate,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,,,,,,,,,,,,,,,,,,,,
http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html,2015-11-29 18:21:18 -0500,DDI-clinical-trial,evidence-supports,Co-administration of a single dose of INVEGA® 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the Cmax and AUC of paliperidone. Dosage reduction for INVEGA® should be considered when INVEGA® is co-administered with valproate after clinical assessment.,ncit:positive,ncit:quantitative,INVEGA,dikbD2R:active-ingredient,dikbD2R:object-drug-of-interaction,12,divalproex sodium,dikbD2R:active-ingredient,dikbD2R:precipitant-drug-of-interaction,1000,SD,Oral,1,QD,Oral,UNK,UNK,50,Percent,Increase,UNK,UNK,UNK,50,Percent,Increase,UNK,UNK,UNK
